Vecabrutinib - Sunesis Pharmaceuticals

Drug Profile

Vecabrutinib - Sunesis Pharmaceuticals

Alternative Names: SNS 062

Latest Information Update: 19 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec; Sunesis Pharmaceuticals
  • Developer Biogen; Sunesis Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Haematological malignancies

Most Recent Events

  • 01 May 2017 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Chronic lymphocytic leukaemia presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 28 Apr 2017 Phase-I/II clinical trials in Haematological malignancies (Second-line therapy or greater) in USA (PO) (NCT03037645)
  • 03 Apr 2017 Pharmacodynamics data from preclinical studies in Haematological malignancies released by Sunesis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top